MNMD Jan 2025 0.500 call
| Previous Close | 11.30 |
| Open | 11.30 |
| Bid | 8.40 |
| Ask | 12.60 |
| Strike | 0.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 11.30 - 11.30 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 16 |
Business WireMindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NEW YORK, June 21, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024.
Business WireMindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK, June 20, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD.
Simply Wall St.Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) 18% loss last week hit both individual investors who own 46% as well as institutions
Key Insights Significant control over Mind Medicine (MindMed) by retail investors implies that the general public has...
